How to break the general decline in H1 performance in 2020 when the reshuffle of the super-billion-dollar infusion market accelerates

In the first half of 2020, the new crown outbreak raged, allowing the large infusion industry to survive a difficult winter.
industry, "Big Three" Colum Pharmaceuticals, Shi Shisi Pharmaceuticals and China Resources Shuanghe all saw a decline in first-half results.
, changes in the performance of leading infusion companies are closely related to the ongoing outbreak.
public data show that in the first half of 2020, the new crown epidemic has affected the normal diagnosis and treatment work of medical institutions, the cumulative number of medical institutions in January-May was 1.143 billion, down 24.30% from the same period a year earlier, the volume of surgery also decreased significantly, resulting in the first half of the large infusion preparation products sales decline, sales revenue fell sharply.
third company's first-half sales fell by double digits from a year earlier.
as industry leaders, all three companies have taken steps to respond positively to the impact of the outbreak.
the strategy is not the same, but all three enterprises have chosen to increase research and development investment.
, in particular Colum Pharmaceuticals, accounted for 10.37 percent of revenue in the first half of the year.
also shows from one side that the industry leader has similar considerations for the future direction of the large infusion industry entering the period of deepening integration.
01 Colum Pharmaceuticals: Increased investment in research and development during the downturn, new drugs bucked the trend on August 30, Colum Pharmaceuticals announced its first half 2020 results.
2020H1 revenue of 7.231 billion yuan, down 18.95 percent year-on-year, and net profit of 203 million yuan, down 72.15 percent year-on-year.
report attributed the decline in first-half results to four points, the first of which was that the new crown outbreak led to a decline in sales of infusion and non-infusion products and a decrease in gross margin.
specific to the segmented business, the company's infusion products achieved operating income of 3,793 million yuan, down 26.76 percent year-on-year, and non-infusion products revenue of 3,252 million yuan, down 11.36 percent year-on-year.
although the overall business sector showed a downward trend, but the new drug sector volume is rapid, the first half of the sales amount reached 922 million yuan, an increase of 22.90% over the same period last year, bucking the trend.
for the new drug sector, Colum Pharmaceuticals has also set up a professional self-employed team of more than 700 people.
to continue to invest more in research and development in the face of falling first-half results.
2020H1, Colum invested 769 million yuan in research and development, up 15.48 percent year-on-year, and accounted for 10.37 percent of sales revenue.
same time, Colum Pharmaceuticals' research and development results during the reporting period, with 12 drugs approved for sale since 2020.
among them, onnitride tablets and cephalosporatin capsules were evaluated consistently, and the hydrochloric acid dapositin tablets, tofatin tablets, and Ingle net tablets expanded the pipeline of men's, autoimmune diseases and diabetes products.
also made good progress in the research and development of innovative drugs, and key progress has been made in the main varieties.
semi-annual report shows that during the reporting period, 13 innovative drug varieties entered the clinical stage, carried out 18 clinical studies, mainly related to malignant tumors, autoimmune, anesthesia analgesia, mental nerve and other major diseases, the second half of the year also plans to promote 14 clinical research varieties, accelerate the promotion of 7 key varieties.
PD-L1 single-anti-A167 critical Phase II clinical studies are in the data cleansing stage and are expected to become the first innovative drug species to be declared for production.
02 Shisi Pharmaceuticals: Diversified business structure, non-large infusion performance bright stone four pharmaceutical group on August 25, announced the company's results for the six months ended June 30, 2020.
report said the group's production and operations were severely affected by the new crown outbreak, the rapid growth trend that had lasted for many years was interrupted, and sales and profits declined significantly.
report showed that Shisty Pharmaceuticals achieved sales revenue of RMB1,617 million, down 19.5% YoY, and net profit of RMB224 million, down 52.7% YoY.
shi four drugs are the three enterprises in the infusion business accounted for the largest proportion of revenue, its large infusion field of all products sales revenue declined.
sales of about 482 million bottles of infusions in the first half of 2020, a decrease of about 38% year-on-year.
, non-PVC standard soft bags achieved revenue of 558 million yuan, down 32.4% YoY, erect bag revenue was 144 million yuan, down 49.5% YoY, plastic bottle sales were 270 million yuan, down 26.1% YoY, and glass bottle infusions were 101 million yuan, down 55.6% YoY.
but the share of large infusions is declining, with 2020H1 accounting for about 66% of total revenue, compared with 84.8% in the same period in 2019, and the company's business is more diversified to share the impact of the outbreak.
, on the other hand, Shisi pharmaceutical non-large infusion business performance is generally outstanding, but also to some extent offset the decline in the performance of large infusions.
sales of ampoule products in the first half of this year were RMB266 million, an increase of about 104.6% year-on-year.
has maintained a high growth rate since 2018, with full-year 2019 revenue of RMB348 million, up 207.7% YoY.
shi shi four drugs in the first half of 2020 also built a new 10 ml PP ampoule water needle production line project, further expand the production capacity of special small-capacity injection products.
other products achieved sales revenue of 223 million yuan, up 108% YoY, mainly from the antiviral drug Abildo and API sales contribution.
abidor capsule hydrochloride as a broad-spectrum antiviral drug in the outbreak of antiviral effect has been affirmed, was included in the national "new coronavirus pneumonia diagnosis and treatment program", but also included in the national 2019 version of the health insurance directory.
during the outbreak, Abidor was allowed to enter 27 provinces and cities to prevent and control the epidemic product catalog or the green channel for drug prevention and control, the first half of the sales revenue of 50.64 million yuan, 19 times more than the same period last year.
the second half of 2019 Shisypharma invested 4 billion yuan in the construction of Hebei Guangxiang Pharmaceutical API project in Bohai New Area, but the impact of the outbreak in the first half of this year production capacity was not fully released.
s earnings report defines the API business as another important segment of the Group's development after injections, and plans to consolidate the API business into a spin-off of the domestic securities market.
research and development, the cost of research and development in 2020H1 was RMB74.75 million, an increase of 26% over the same period last year, and the share of research and development expenditure in sales revenue was about 4.62%.
because the core of Shisi pharmaceutical business is large infusion, its research and development scale in three relatively small.
report shows that in the first half of the year Shisi pharmaceutical further promote innovative drug and generic drug research and development and generic drug consistency evaluation progress, a total of 72 reported research and development projects, including three consistent evaluation and a new class of NP-01 clinical applications, the drug is also Shisi pharmaceutical first declared innovative drug 03 China Resources double Crane: Infusion and chronic disease business decline, plus code research and development look forward to transformation according to China Resources Shuanghe august 25 released the 2020 in-year report, its first-half operating income of 4.15 billion yuan, down 14.77 percent year-on-year;
of the three major business platforms, sales revenue from the chronic disease and infusion business decreased, except for the fact that revenue from the specialist business remained flat compared with the same period last year.
Among them, the infusion business was the most seriously affected by the outbreak of new crown pneumonia, revenue decreased by 25% YoY, basic infusion sales decreased the most, reached 27%; Sales in the pharmaceutical sector increased by 15% year-on-year and in the psycho/neurological sector by 12% year-on-year, both offsetting the decline in sales revenue in the pediatric drug sector, and China Resources Shuanghe did not disclose specific figures and percentages of revenue for each of the three business platforms, but reported that revenue from its non-infusion business had exceeded infusion business since 2015 and was increasing year by year.
Although the most affected infusion business is no longer the core of China Resources Shuanghe's revenue, but as a leading enterprise in the large infusion industry, infusion business is still the basis for the long-term development of China Resources Shuanghe, for its follow-up pipeline research and development and strategic transformation to provide a stable guarantee of cash flow.
in the face of declining performance, China Resources Shuanghe also chose to increase investment in research and development.
2020H1 research and development expenses increased by 30.53 percent year-on-year to 110 million yuan, but the proportion of research and development investment in sales revenue is not high, only 2.65 percent.
results show that China Resources Shuanghe in 2019 identified a research and development innovation strategy to continue to increase research and development investment, plans to achieve research and development innovation transformation in three stages.
2020, the company has achieved positive results in research and development innovation, with two approvals for generic drugs, two approvals for generic drugs, and eight consistent evaluations or declarations for generics projects.
year, the company has 9 products through the consistent evaluation.